Latest Product Development News

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

TradeWindow Holdings Limited has announced a share purchase plan to raise up to NZ$1 million by issuing new shares to eligible New Zealand and Australian shareholders, opening on 2 February 2026.

TradeWindow has launched a NZ$1 million Share Purchase Plan to accelerate its Freight AI operating system development and support growth across Australasia. This follows a successful NZ$5.7 million placement, signalling strong investor confidence in the company’s tech-driven future.

Manuka Resources has secured a US$22.5 million loan facility and completed a A$15 million capital raise, positioning itself for a production restart in late Q2 2026 amid soaring silver and gold prices.

Activeport Group Ltd reported steady Q2 FY26 revenue with new contracts starting to contribute and a 5% increase in annualised recurring revenue to $6.3 million. The company also reduced cash burn significantly and strengthened its cash position to support growth.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

Wide Open Agriculture has made significant strides in expanding its intellectual property and commercial footprint, including a new patent for lupin protein milk and first sales of lupin oil, while progressing plans for a large-scale manufacturing facility in Western Australia.

Aguia Resources has secured critical financing and advanced key projects in Brazil and Colombia, setting the stage for phosphate production in early 2026 and improved gold output. Meanwhile, the company streamlines operations and divests non-core assets to sharpen its focus.

International Graphite Limited has secured key approvals and funding to progress its Collie Micronising Facility and European Expandable Graphite Project, positioning itself as a major supplier outside China.

Merino & Co. reported steady progress in Q2 FY26 with growing demand from China and ongoing investments in brand and manufacturing, despite a tightening cash position.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

Thrive Tribe Technologies reported a $186,000 net operating cash outflow in Q2 FY26, offset by a $300,000 equity raise to fund growth initiatives and operational expansion.